Skip to main content Help with accessibility Skip to main navigation

UPADACITINIB prolonged-release tablets (Rinvoq®▼) for active non-radiographic axial spondyloarthritis

CCG Approval Status:

Ha
Kn
Li
SF
SS
SH
Wa
WL
Wi
Date Added: 23 - Feb - 2023
Body System:
Red
UPADACITINIB prolonged-release tablets (Rinvoq®▼) for active non-radiographic axial spondyloarthritis

The Cheshire and Merseyside Interim Area Prescribing Group recommends the prescribing of UPADACITINIB prolonged-release tablets (Rinvoq®▼), by specialists only, for active non-radiographic axial spondyloarthritis in accordance with NICE TA861.

NHS Cheshire and Merseyside APPROVED